Ken Griffin Cardiol Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,900 shares of CRDL stock, worth $5,978. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,900
Previous 5,200
5.77%
Holding current value
$5,978
Previous $10,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
7.22MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X03.12MShares$3.8 Million2.61% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD882KShares$1.08 Million0.23% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$970,6620.31% of portfolio
-
Cambridge Investment Research Advisors, Inc.331KShares$403,2160.0% of portfolio
-
Envestnet Asset Management Inc310KShares$377,8140.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $75.6M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...